fs from the Co
Auryxia is currently approved for use in the U.S. for the control of serum phosphorus levels in patients with end-stage renal disease requiring dialysis.
Keryx, with this sNDA submission, is seeking to expand the indication for Auryxia to include the treatment of iron deficiency anemia (IDA) in patients with non-dialysis dependent chronic kidney disease (NDD-CKD).
............................................
So their goal is to expand , with this approval , into the anemia market ....a far larger market .
Problem is that FGEN has better data then them , so far , and is only about 2 yrs behind re FDA approval.
KERX has also filed to raise $75m , which explains the sell off this am .
My quick take .
Auryxia may be a better drug then current SOC for elevated phosphorous levels but payers require patient failure on the available generic first , then create a paper work challenge for the MD prescribing .
Kiwi
